David Edmund Szymkowski

List of Publications by Year
in descending order

56 papers	3,371 citations	186265 28 h-index	149698 56 g-index
61 all docs	61 docs citations	61 times ranked	4216 citing authors

#	Article	IF	Citations
1	Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and FcÎ³ receptor IIb in non-autoimmune-prone and SLE-prone mice. Journal of Translational Autoimmunity, 2021, 4, 100075.	4.0	9
2	Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcÎ³RIIb on Liver Sinusoidal Endothelial Cells by Endocytosis. Journal of Immunology, 2021, 206, 1284-1296.	0.8	6
3	Topical Administration of a Soluble TNF Inhibitor Reduces Infarct Volume After Focal Cerebral Ischemia in Mice. Frontiers in Neuroscience, 2019, 13, 781.	2.8	25
4	Inhibition of TNF reduces mechanical orofacial hyperalgesia induced by Complete Freundâ€™s Adjuvant by a TRPV1-dependent mechanism in mice. Pharmacological Reports, 2017, 69, 1380-1385.	3.3	11
5	Trypanosoma brucei growth control by TNF in mammalian host is independent of the soluble form of the cytokine. Scientific Reports, 2017, 7, 6165.	3.3	8
6	Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. JCI Insight, 2017, 2, .	5.0	72
7	Hippocampal TNFÎ± Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy. ENeuro, 2017, 4, ENEURO.0105-17.2017.	1.9	88
8	Harnessing Fc receptor biology in the design of therapeutic antibodies. Current Opinion in Immunology, 2016, 40, 78-87.	5.5	59
9	Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination. Journal of Neuroscience, 2016, 36, 5128-5143.	3.6	113
10	Transmembrane TNFâ€Î± is sufficient for articular inflammation and hypernociception in a mouse model of gout. European Journal of Immunology, 2016, 46, 204-211.	2.9	67
11	Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 Ã— Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma. Blood, 2015, 126, 1798-1798.	1.4	26
12	Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcÎ³RIIb and CD19. MAbs, 2014, 6, 991-999.	5.2	28
13	Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. Journal of Neuroinflammation, 2014, 11, 159.	7.2	62
14	Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. Journal of Neuroinflammation, 2014, 11, 203.	7.2	79
15	Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Antiâ€CD19 Antibody That Coengages B Cell Antigen Receptor Complex and FcÎ³ Receptor IIb Inhibitory Receptor. Arthritis and Rheumatology, 2014, 66, 1153-1164.	5.6	51
16	Central but not peripheral administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. Journal of Neuroimmunology, 2014, 275, 114-115.	2.3	0
17	Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosisâ€"Directed Therapeutics. Journal of Immunology, 2014, 192, 4122-4133.	0.8	18
18	A1.84â€…Switching off B cells by Fc-engineered anti-CD19 antibody (XmAb5871). Annals of the Rheumatic Diseases, 2014, 73, A37.1-A37.	0.9	0

#	Article	IF	Citations
19	Immunotherapy with Long-Lived Anti-CD123 Ã— Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia. Blood, 2014, 124, 2316-2316.	1.4	27
20	Immunotherapy with Long-Lived Anti-CD20 Ã— Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias. Blood, 2014, 124, 3111-3111.	1.4	12
21	Immunotherapy with Long-Lived Anti-CD38 Ã— Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma. Blood, 2014, 124, 4727-4727.	1.4	14
22	Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis. Inflammatory Bowel Diseases, 2013, 19, 246-253.	1.9	56
23	Immune suppression in cynomolgus monkeys by XPro9523. MAbs, 2013, 5, 384-396.	5.2	23
24	Suppression of mast cell degranulation through a dual-targeting tandem IgEâ€“IgG Fc domain biologic engineered to bind with high affinity to FcÎ³RIIb. Immunology Letters, 2012, 143, 34-43.	2.5	28
25	Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcÎ³RIIb with Fc-engineered antibody. Journal of Allergy and Clinical Immunology, 2012, 129, 1102-1115.	2.9	81
26	Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis. Clinical and Experimental Immunology, 2012, 168, 165-177.	2.6	25
27	Inhibition of Soluble Tumor Necrosis Factor Ameliorates Synaptic Alterations and Ca2+ Dysregulation in Aged Rats. PLoS ONE, 2012, 7, e38170.	2.5	47
28	Suppression Of IgE Production By XmAb7195, An Fc-Engineered Antibody That Specifically Coengages Inhibitory Receptor Fc?RIIb With IgE-BCR. , 2011, , .		0
29	Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-ÎºB. Brain, 2011, 134, 2722-2735.	7.6	85
30	Allergic Lung Inflammation Is Mediated by Soluble Tumor Necrosis Factor (TNF) and Attenuated by Dominant-Negative TNF Biologics. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 731-739.	2.9	25
31	Antibody-Mediated Coengagement of FcÎ³RIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus. Journal of Immunology, 2011, 186, 4223-4233.	0.8	142
32	Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain, 2011, 134, 2736-2754.	7.6	174
33	Roles of Soluble and Membrane TNF and Related Ligands in Mycobacterial Infections: Effects of Selective and Non-selective TNF Inhibitors During Infection. Advances in Experimental Medicine and Biology, 2011, 691, 187-201.	1.6	29
34	Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood, 2010, 116, 575-583.	1.4	63
35	Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. Journal of Hepatology, 2010, 53, 1059-1068.	3.7	56
36	Dominantâ€Negative Tumor Necrosis Factor Protects from<i>Mycobacterium bovis</i>Bacillus Calmetteâ€GuÃ©rin (BCG) and Endotoxinâ€Induced Liver Injury without Compromising Host Immunity to BCG and<i>Mycobacterium tuberculosis</i>. Journal of Infectious Diseases, 2009, 199, 1053-1063.	4.0	48

#	Article	IF	Citations
37	Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcÎ³RIIb with Fc-engineered antibodies. Molecular Immunology, 2008, 45, 3926-3933.	2.2	128
38	Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection. Journal of Immunology, 2007, 179, 1872-1883.	0.8	148
39	Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis. PLoS ONE, 2006, 1, e108.	2.5	116
40	Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease. Journal of Neuroscience, 2006, 26, 9365-9375.	3.6	331
41	Timely lessons for target-based discovery of anti-inflammatory drugs. Drug Discovery Today, 2005, 10, 14-17.	6.4	1
42	Creating the next generation of protein therapeutics through rational drug design. Current Opinion in Drug Discovery & Development, 2005, 8, 590-600.	1.9	21
43	Rational optimization of proteins as drugs: a new era of ?medicinal biology?. Drug Discovery Today, 2004, 9, 381-383.	6.4	6
44	Target validation joins the pharma fold. Targets, 2003, 2, 8-9.	0.3	4
45	Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants. Science, 2003, 301, 1895-1898.	12.6	222
46	Phorbol 12-Myristate 13-Acetate Up-regulates the Transcription of MUC2Intestinal Mucin via Ras, ERK, and NF-ÎºB. Journal of Biological Chemistry, 2002, 277, 32624-32631.	3.4	93
47	MUC17, a Novel Membrane-Tethered Mucin. Biochemical and Biophysical Research Communications, 2002, 291, 466-475.	2.1	187
48	Too many targets, not enough target validation. Drug Discovery Today, 2001, 6, 397.	6.4	11
49	Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Research, 2000, 48, 187-196.	4.1	27
50	Cloning of the Amino-terminal and 5â€²-Flanking Region of the Human MUC5AC Mucin Gene and Transcriptional Up-regulation by Bacterial Exoproducts. Journal of Biological Chemistry, 1998, 273, 6812-6820.	3.4	160
51	Developing antisense oligonucleotides from the laboratory to clinical trials. Drug Discovery Today, 1996, 1, 415-428.	6.4	51
52	Hypersensitivity to Cisplatin in Mouse Leukemia L1210/0 Cells: An XPG DNA Repair Defect. , 1996, , 317-326.		0
53	An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Molecular and Cellular Biology, 1995, 15, 290-297.	2.3	28
54	Electron Microscopy of DNA Excision Repair Patches Produced by Human Cell Extracts. Journal of Molecular Biology, 1993, 231, 251-260.	4.2	16

#	Article	IF	Citations
55	Identification and characterization of aDictyostelium discoideumribosomal protein gene. Nucleic Acids Research, 1990, 18, 4695-4701.	14.5	17
56	ADictyostelium discoideumcDNA coding for a protein with homology to the rat ribosomal protein L7. Nucleic Acids Research, 1989, 17, 5393-5393.	14.5	15